

O I P E  
JAN 11 2006  
14P88  
PATENT & TRADEMARK OFFICE

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>		<b>ATTY. DOCKET NO.:</b> <b>39766-0114A</b>		<b>SERIAL NO.:</b> <b>10/619,754</b>			
		<b>APPLICANT :</b> Hans KOLL, et al.					
		<b>FILING DATE:</b> July 14, 2003		<b>GROUP:</b> 1651			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	US 2004/0132097 A1	07/18/2004	Sarah Bacus, et al.	436	7.1		
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
ALH	WO 2004/000102 A2	12/31/2003	PCT	A61B		<input type="checkbox"/>	<input checked="" type="checkbox"/>
ALH	WO 2004/053497 A2	06/24/2004	PCT	G01N	33/574	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
EXAMINER	/Anne Holleran/ (09/02/2006)						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. PATENT AND TRADEMARK OFFICE  
OCT 13 2005  
14938

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>		<b>ATTY. DOCKET NO.:</b> <b>39766-0114A</b>		<b>SERIAL NO.:</b> <b>10/619,754</b>	
		<b>APPLICANT :</b> Hans KOLL et al.			
		<b>FILING DATE:</b> July 14, 2003		<b>GROUP:</b> 1651	

#### U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
ALH	5,811,098 A	09/22/1998	Plowman et al.	424/178.1	530/387.3	
ALH	6,417,168 B1	07/09/2002	Greene et al.	514/44	514/44	

#### FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>

#### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ALH	Agus et al., "Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth", Cancer Cell, Vol. 2, pp 127-137, August 2002.
	Quian et al., p185 <sup>c-neu</sup> and epidermal growth factor receptor associate into a structure composed of activated kinases", Proceedings of the National Academy of Sciences USA, Vol. 89, pages 1330-1334, February 1992.
↓	Tzahar et al. "The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands", Biochimica et Biophysica Acta, Vol. 1377, pp M25-M37, 1998.


EXAMINER /Anne Holleran/ (09/02/2005) CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>		<b>ATTY. DOCKET NO.:</b> <b>39766-0114A</b>		<b>SERIAL NO.:</b> <b>10/619,754</b>			
		<b>APPLICANT :</b> Hans KOLL, et al.					
		<b>FILING DATE:</b> July 14, 2003		<b>GROUP:</b> 1651			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
ALH	US 2004/0229380 A1	11/18/2004	Chan Hui, et al.	436	518		
	US 2004/0229293 A1	11/18/2004	Chan Hui, et al.	435	7.2		
	US 2003/0190689 A1	10/09/2003	Crosby, et al.	435	7.23		
	US 2004/0197835 A1	10/07/2004	Chan Hui, et al.	435	7.2		
	US 2004/0126818 A1	07/01/2004	Chan Hui, et al.	435	7.2		
	US 2004/0229294 A1	11/18/2004	Chan Hui, et al.	435	7.2		
<u>ALH</u>	<u>US 2004/0229380 A1</u>	<u>11/18/2004</u>	<u>Chan Hui, et al.</u>	<u>436</u>	<u>518</u>		
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
ALH	WO 03/087761 A2	10/23/2003	PCT	G01N		<input type="checkbox"/>	<input type="checkbox"/>
ALH	WO 2004/092353 A2	10/28/2004	PCT	C12N		<input type="checkbox"/>	<input type="checkbox"/>
ALH	WO 2004/011900 A2	02/05/2004	PCT	G01N		<input type="checkbox"/>	<input type="checkbox"/>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
<b>EXAMINER</b>	<b>/Anne Holleran/ (09/02/2006)</b>						

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 <b>INFORMATION DISCLOSURE STATEMENT</b> <b>PTO-1449</b>	ATTY. DOCKET NO.	SERIAL NO.					
	39766-0114	10/619,754					
	APPLICANT Hans Koll, et al.						
	FILING DATE July 14, 2003		GROUP: To Be Determined				
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
ALH	4,968,603	11/6/90	Slamon et al.	435	6		
	5,183,884	2/2/93	Kraus, et al.	536	23.5		
	5,480,968	2/2/96	Kraus, et al.	530	326		
	5,641,869	6/24/97	Vandlen et al.	530	413		
	5,677,171	10/14/97	Hudziak et al.	435	240.27		
	5,783,186	7/21/98	Arakawa	424	143.1		
	5,821,337	10/13/98	Carter et al.	530	387.3		
	5,824,311	10/20/98	Greene et al.	424	138.1		
	6,399,743	6/4/02	Majumdar	530	324		
	6,627,400	9/30/03	Singh et al.	435	6		
▼	2003/0096373	5/22/03	Majumdar et al.	435	70.21		
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
ALH	599,274	11/23/93	EP	C12N	15/12	<input type="checkbox"/>	<input type="checkbox"/>
▼	WO 01/00245	1/4/01	PCT	A61K	47/48	<input type="checkbox"/>	<input type="checkbox"/>
▼	WO 94/00136	1/6/94	PCT	A61K	35/14	<input type="checkbox"/>	<input type="checkbox"/>
▼	WO 94/22478	10/13/94	PCT	A61K	39/395	<input type="checkbox"/>	<input type="checkbox"/>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
ALH	Aasland et al. "Expression of oncogenes in thyroid tumours: Coexpression of c-erbB2/neu and c-erbB" <i>Br. J. Cancer</i> 57:358-363 (1988)						
ALH	Arteaga et al. "p185c-erbB-2 Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair" <i>Cancer Research</i> 54:3758-3765 (1994)						
ALH	Azzoli C.G. et al "Trastuzumab in the Treatment of Non-Small Cell Lung Cancer" <i>Seminars in Oncol</i> 29(1) Suppl 4:59-65 (2002)						
EXAMINER	/Anne Holleran/ <i>10/02/2006</i> CONSIDERED						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b> <b>RECEIVED</b> <b>O I P E JC 10 30 2003</b> <b>RECEIVED</b> <b>U.S. PATENT AND TRADEMARK OFFICE</b> <b>ALH</b>		ATTY. DOCKET NO.	SERIAL NO.
		39766-0114	10/619,754
		APPLICANT Hans Koll, et al.	
<b>FILING DATE</b> July 14, 2003		GROUP: To Be Determined	
<b>U.S. PATENT DOCUMENTS</b>			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
Bacus et al. "Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells" <i>Cancer Research</i> 52:2580-2589 (1992)			
Bacus et al. "Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated With Loss of Cell Surface HER-2/neu Antigen" <i>Molecular Carcinogenesis</i> 3:350-362 (1990)			
Bange et al. "Molecular targets for breast cancer therapy and prevention" <i>Nature Medicine</i> 7(5):548-552 (2001)			
Baselga et al. "Receptor Blockade with Monoclonal Antibodies as Anti-Cancer Therapy" <i>Pharmac. Ther.</i> 64:127-154 (1994)			
Baselga et al. "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185her2 Monoclonal Antibody in Patients with HER2/neu-Overexpressing Metastatic Breast Cancer" <i>J Clin Oncol</i> 14(3):737-744 (1996)			
Borst et al. "Oncogene Alterations in Endometrial Carcinoma" <i>Gynecol. Oncol.</i> 38:364 (1990)			
Brennan P.J. et al. "HER2/Neu: mechanisms of dimerization/oligomerization" <i>Oncogene</i> 19:6093-6101 (2000)			
Brockhoff et al. "Epidermal Growth Factor Receptor, c-erbB2 and c-erbB3 Receptor Interaction, and Related Cell Cycle Kinetics of SK-BR-3 and BT474 Breast Carcinoma Cells" <i>Cytometry</i> 44:338-348 (2001)			
Carraway et al. "A Neu Acquaintance for ErbB3 and ErbB 4: A Role for Receptor Heterodimerization in Growth Signaling" <i>Cell</i> 78:5-8 (1994)			
Carraway et al. "Neuregulin-2 a new ligand of ErbB3/ErbB4-receptor tyrosine kinases" <i>Nature</i> 387:512-516 (1997)			
Chang et al. "Ligands for ErbB-family receptors encoded by a neuregulin-like gene" <i>Nature</i> 387:509-512 (1997)			
Chen et al. "Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc" <i>Mol Cell Biol</i> 18(9): 5178-5188 (1998)			
Chow et al. "Expression Profiles of ErbB Family Receptors and Prognosis in Primary Transitional Cell Carcinoma of the Urinary Bladder" <i>Clinical Cancer Research</i> 7:1975-1962 (2001)			
Cohen et al. "Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract" <i>Oncogene</i> 4:81-88 (1989)			
Clark et al. "Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the ras signaling pathway." <i>Int'l. J. Cancer</i> 65:186-191 (1996)			


**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>   PTO-1449		ATTY. DOCKET NO. <b>39766-0114</b>	SERIAL NO. <b>10/619,754</b>
		APPLICANT Hans Koll, et al.	
		FILING DATE July 14, 2003	GROUP: To Be Determined
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	D'souza et al. "Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene" <i>PNAS (USA)</i> 91:7202-7206 (1994)		
	DiGiovanna et al. "Active Signaling by HER-2/neu in Subpopulation of HER-2/neu-overexpressing Ductal Carcinoma in Situ: Clinicopathological Correlates" <i>Cancer Research</i> 62:6667-6673 (2002)		
	Drebin et al. "Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies" <i>Cell</i> 41:695-706 (1985)		
	Drebin et al. "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects" <i>Oncogene</i> 2:273-277 (1988)		
	Earp et al. "Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research" <i>Breast Cancer Research and Treatment</i> 35:115-132 (1995)		
	Esteva et al. "Expression of erbB/HER Receptors, Heregulin and P38 in Primary Breast Cancer using Quantitative Immunohistochemistry" <i>Path Oncol Res</i> 7(3):171-177 (2001)		
	Fendly et al. "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <i>Cancer Research</i> 50:1550-1558 (1990)		
	Fukushige et al. "Localization of a Novel v-erbB-Related Gene, c-erbB-2, on Human Chromosome 17 and Its Amplification in a Gastric Cancer Cell Line" <i>Mol and Cell Biol</i> 6(3):995-968 (1986)		
	Geurin et al. "Overexpression of Either c-myc or c-erbB-2/neu Proto-Oncogenes in Human Breast Carcinomas: Correlation with Poor Prognosis" <i>Oncogene Res</i> 3:21-31 (1988)		
	Graus-Porta et al. "ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling" <i>EMBO J</i> 16(7):1647-1655 (1997)		
	Groenen et al. "Structure-Function Relationships for the EGF/TGF- $\alpha$ Family of Mitogens" <i>Growth Factors</i> 11:235-257 (1994)		
	Gu et al. "Overexpression of her-2/neu in human prostate cancer and benign hyperplasia" <i>Cancer Letters</i> 99:185-189 (1996)		
	Hancock et al. "A Monoclonal Antibody against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines" <i>Cancer Res</i> 51:4575-4580 (1991)		
	Harari et al. "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase" <i>Oncogene</i> 18:2681-2689 (1999)		
✓	Harwerth et al. "Monoclonal Antibodies against the Extracellular Domain of the erbB-2 Receptor Function as a Partial Ligand Agonists" <i>J. Biol Chem</i> 267:15160-15167 (1992)		
EXAMINER	/Anne Holleran/ (09/02/2006) DATE CONSIDERED		


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b> <b>PTO-1449</b>		ATTY. DOCKET NO. <b>39766-0114</b>	SERIAL NO. <b>10/619,754</b>
		APPLICANT Hans Koll, et al.	
		FILING DATE July 14, 2003	GROUP: To Be Determined
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
ALH	Holmes et al. "Identification of Heregulin, a Specific Activator of p185erbB2" <i>Science</i> 256:1205-1210 (1992)		
	<i>Horizons in Cancer Therapeutics: From Bench to Bedside</i> 2(2) (2001) Miniscus Educational Institute Pennsylvania (entire volume)		
	Hudziak et al. "p185HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <i>Mol Cel Biol</i> 9(3): 1165-1172 (1989)		
	Jong et al. "Mechanism of ErbB-1 and ErbB-2 Hetero-oligomerization" <a href="http://mrmcrad6.army.mil/bcrp/era/abstracts2002/P21_EGF_Superfamily/P21_combined.pdf">http://mrmcrad6.army.mil/bcrp/era/abstracts2002/P21_EGF_Superfamily/P21_combined.pdf</a> <i>June 2002</i>		
	Kasprzyk et al. "Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies" <i>Cancer Research</i> 52:2771-2776 (1992)		
	Kern et al. "p185neu Expression in Human Lung Adenocarcinomas Predicts Shortened Survival" <i>Cancer Res.</i> 50:5184 (1990)		
	King et al. "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma" <i>Science</i> 229:974 (1985)		
	Klapper et al. "A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 block crosstalk with growth factor receptors" <i>Oncogene</i> 14:2099-2109 (1997)		
	Kotts et al. "Differential Growth Inhibition of Human Carcinoma Cells exposed to Monoclonal Antibodies Directed against the Extracellular Domain of the HER2/ERBB2" <i>In Vitro</i> 26(3):59A (1990)		
	Kraus et al. "Isolation and characterization of ERBB3 a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors" <i>PNAS (USA)</i> 86:9193-9197 (1989)		
	Kumar et al. "Regulation of Phosphorylation of the c-erbB-2/Her2 Gene Product by a Monoclonal Antibody and Serum Growth Factor(s) in Human Mammary Carcinoma Cells" <i>Mol and Cell Biol</i> 11(2):979-986 (1991)		
	Lee et al. "Transforming Growth Factor $\alpha$ : Expression Regulation and Biological Activities" <i>Pharm Rev</i> 47:51-85 (1995)		
	Lemke G. "Review Neuregulins in Development" <i>Mol and Cell Neurosci</i> 7:247-262 (1996)		
	Levi et al. "The Influence of Heregulins on Human Schwann Cell Proliferation" <i>Journal of Neuroscience</i> 15(2):1329-1340 (1995)		
▼	Lewis et al. "Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies" <i>Cancer Immunol. Immunother</i> 37:255-263 (1993)		
EXAMINER		/Anne Holleran/ (08/02/2006) CONSIDERED	


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>  		ATTY. DOCKET NO. <b>39766-0114</b>	SERIAL NO. <b>10/619,754</b>
		APPLICANT Hans Koll, et al.	
		FILING DATE July 14, 2003	GROUP: To Be Determined
		<b>U.S. PATENT DOCUMENTS</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
ALH	Lewis et al. "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness" <i>Cancer Research</i> 56:1457-1465 (1996)		
	Maier et al. "Requirements for the Internalization of a Murine Monoclonal Antibody Directed against the HER-2/neu Gene Product c-erbB-2" <i>Cancer Res</i> 51:5361-5369 (1991)		
	Masui et al. "Growth Inhibition of Human Tumor Cells in Athymic Mice by Antiepidermal Growth Factor Receptor Monoclonal Antibodies" <i>Cancer Research</i> 44:1002-1007 (1984)		
	McCann et al. "c-erbB-2 Oncoprotein Expression in Primary Human Tumors" <i>Cancer</i> 65:88-92 (1990)		
	McKenzie et al. "Generation and characterization of monoclonal antibodies specific for the human <i>neu</i> oncogene product, p185" <i>Oncogene</i> 4:543-548 (1989)		
	Meric et al. "ZD1839 "Iressa"" <i>Bull Cancer</i> 87(12):873-876 (2000)		
	Mitchell "Peptide Regulatory Factors Post-Receptor Signaling Pathays" <i>Lancet</i> 1:765-767 (1989)		
	Moasser et al. "The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells" <i>Cancer Res.</i> 61(19):7184-7188 (2001)		
	Morrissey et al. "Axon-induced mitogenesis of human Schwann cells involves heregulin and p185erbB2" <i>PNAS USA</i> 92:1431-1435 (1995)		
	Myers et al. "Biological Effects of Monoclonal Antireceptor Antibodies Reactive with <i>neu</i> Oncogene Products p185neu" <i>Meth. Enzym.</i> 198:277-290 (1991)		
	Nagy et al. "EGF-Induced Redistribution of erbB2 on Breast Tumor Cells: Flow and Image Cytometric Energy Treanfer Measurements" <i>Cytometry</i> 32:120-131 (1998)		
	Norman P. "OSI-774 OSI Pharmaceuticals" <i>Curr. Opin. Investig. Drugs</i> 2(2):298-304 (2001)		
	Nomanno et al. "Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth" <i>Ann. Oncol.</i> 13:65-72 (2002)		
	Park et al. "Amplification, Overexpression, and Rearrangement of the erbB-2 Protooncogene in Primary Human Stomach Carcinomas" <i>Cancer Res</i> 49:6605-6609 (1989)		
	Pietras et al. "Antibody ot HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells" <i>Oncogene</i> 9:1829-1838 (1994)		
↓	Plowman et al "Heregulin induces tyrosine phosphorylation of HER4/p180erbB4" <i>Nature</i> 366:473-475 (1993)		
EXAMINER	/Anne Holleran/		DATE CONSIDERED 10/02/2006


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>   <b>PTO-1449</b>		ATTY. DOCKET NO. <b>39766-0114</b>	SERIAL NO. <b>10/619,754</b>
		APPLICANT Hans Koll, et al.	
		FILING DATE July 14, 2003	GROUP: To Be Determined
		<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>	
ALH	Plowman et al. "Ligand-specific activation of HER4/p180erbB4 a fourth member of the epidermal growth factor receptor family" <i>PNAS USA</i> 90:1746-1750 (1993)		
	Olayioye et al. "The ErbB signaling network: receptor heterodimerization in development and cancer" <i>EMBO Journal</i> 19(13):3159-3167 (2000)		
	<i>Oncology Biotherapeutics Anti-EGFR therapy: A new targeted approach to cancer treatment</i> 2(1) (2002) Cancer Communications Limited, Germany (entire volume)		
	Partik et al. "Inhibition of epidermal-growth-factor-receptor-dependent signaling by tyrophostins A25 and AG1478 block growth and induces apoptosis in colorectal tumor cells in vitro" <i>J. Cancer Res Clin Oncol.</i> 125: 379-388 (1999)		
	Pollack et al. "Inhibitions of epidermal growth factor receptor-associated tyrosiphosphorylation in human carcinomas with CP-358, 774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice" <i>JPET</i> 291(2):739-748 (1999)		
	Raymond et al. "Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy" <i>Drugs</i> 60(Suppl 1):15-23; discussion 41-42 (2000)		
	Ross et al. "Prognostic Singificance of HER-2/neu Gene Amplification Status by Florescence in Situ Hybridization of Prostate Carinoma" <i>Cancer</i> 79:2162-2170		
	Ross et al. "HER-2/neu Gene Amplification Status in Prostate Cancer by Florescence in Situ Hybridization" <i>Hum. Pathol.</i> 28(7):827-833 (1997)		
	Sadasivan et al. "Overexpression of HER-2/Neu may be an indication of poor prognosis in prostate cancer" <i>J. Urol.</i> 150:126-131 (1993)		
	Sarup et al. "Characterization of an Anti-p185HER2 Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth" <i>Growth Regulation</i> 1:72-82 (1991)		
	Schaefer et al. "γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175" <i>Oncogene</i> 15:1385-1394 (1997)		
	Scott et al. "p185HER2 Signal Transduction in Breast Cancer Cells" <i>J. Biol Chem</i> 266(22):14300-14305 (1991)		
	Sewell, et al. "Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD1839 ("Iressa")" <i>Br. J. Cancer</i> 86(3):456-462 (2000)		
	Shawver et al. "Ligand-like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate With And Are Not Required For Growth Inhibition Of Human Carcinoma Cells" <i>Cancer Res.</i> 54:1367-1373 (1994)		
▼	Shepard et al. "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protoonogene to the Clinic" <i>J. Clin. Immunology</i> 11(3):117-127 (1991)		
EXAMINER	/Anne Holleran/ (09/02/2006)	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>   <b>PTO-1449</b>		ATTY. DOCKET NO. <b>39766-0114</b>	SERIAL NO. <b>10/619,754</b>
		APPLICANT Hans Koll, et al.	
		FILING DATE July 14, 2003	GROUP: To Be Determined
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
ALH	Slamon et al. "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <i>Science</i> 235:177-182 (1987)		
	Slamon et al. "Studied of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer" <i>Science</i> 244:707-712 (1989)		
	Sliwkowski et al "Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin" <i>J. Biol Chem</i> 269(20):14661-14665 (1994)		
	Stancovski et al. "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth" <i>PNAS (USA)</i> 88:8691-8695 (1991)		
	"Structure-function relationship of EGF-like growth factors" <a href="http://www-celbi.sci.kun.nl/project1.htm">www-celbi.sci.kun.nl/project1.htm</a> (6/25/03)		
	Tagliabue et al. "Selection of Monoclonal Antibodies which Induce Internalization and Phosphorylation of p185HER2 and Growth Inhibition of Cells with HER2/neu Gene Amplification" <i>Int J Cancer</i> 47:933-937 (1991)		
	Tang C. "Coexpression of EGFRvIII/ErbB in Human Breast Cancer" <a href="http://dcb.nci.nih.gov/abstract.cfm?ID=6522728">http://dcb.nci.nih.gov/abstract.cfm?ID=6522728</a> (Abstract only)		
	Thor et al. "Activation (Tyrosine Phosphorylation) of ErbB-2 (HER-2/neu): A Study of Incidence and Correlation with Outcome in Breast Cancer" <i>J. of Clin. Onc.</i> 18(18):3230-3239 (2000)		
	Vitetta et al. "Monoclonal Antibodies as Agonists: An Expanded Role for Their Use in Cancer Therapy" <i>Cancer Research</i> 54:5301-5309 (1994)		
	Weiner et al. "Expression of the <i>neu</i> Gene-encoded Protein (P185 <i>neu</i> ) in Human Non-Small Cell Carcinomas of the Lung" <i>Cancer Res.</i> 50:421-425 (1990)		
	Williams et al. "Expression of c-erbB-2 in Human Pancreatic Adenocarcinomas" <i>Pathobiology</i> 59:46-52 (1991)		
	Wu et al. "Apoptosis Induced by an Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in a Human Colorectal Carcinoma Cell Line and Its Delay by Insulin" <i>J. Clin. Invest.</i> 95:1897-1905 (1995)		
	Xia et al. "Combination of EGFR, HER-2 <i>neu</i> and HER-3 Is a Stronger Predictor for the Outcome of Oral Squamous Cell Carcinoma Than Any Individual Family Members" <i>Clinical Cancer Research</i> 5:4164-4174 (1999)		
↓	Xu et al. "Antibody-Induced Growth Inhibition is Mediated Through Immunochemically and Functionally Distinct Epitopes on the Extracellular Domain of the c-erbB-2 (HER-2/neu) GeneProduct p185" <i>Int J. Cancer</i> 53:401-408 (1993)		
EXAMINER	/Anne Holleran/ (09/02/2006)	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>   <b>PTO-1449</b>	ATTY. DOCKET NO.	SERIAL NO.
	39766-0114	10/619,754
	APPLICANT Hans Koll, et al.	
	FILING DATE July 14, 2003	GROUP: To Be Determined
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
ALH	Yarden "ErbB-2 ErbB-3 Heterodimeric Receptor of Carcinomas" <a href="http://dcb.nci.nih.gov/abstract.cfm?ID=6513047">http://dcb.nci.nih.gov/abstract.cfm?ID=6513047</a> (Abstract only)	
	Yonemura et al "Evaluation of Immunoreactivity for erbB-2 Protein as a marker of Poor Short Term Prognosis in Gastric Cancer" <i>Cancer Res</i> 51:1034-1038 (1991)	
	Zhau et al. "Amplification and Expression of the c-erb B-2/neu Proto-Oncogene in Human Bladder Cancer" <i>Mol. Carcinog.</i> 3:254-257 (1990)	
	Zhang et al. "New Perspectives on Anti-Her2/neu Therapeutics" <i>Drug News Perspect</i> 13(6):325-329 (2000)	
↓	Zhang et al. "Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4" <i>PNAS (USA)</i> 94:9562-9567 (1997)	
EXAMINER	/Anne Holleran/ (09/03/2006) CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.